Radiogenomics in the Era of Advanced RadiotherapyCitation formats

  • Authors:
  • M. R.S. Brothwell
  • C. M. West
  • A. M. Dunning
  • N. G. Burnet
  • G. C. Barnett

Standard

Radiogenomics in the Era of Advanced Radiotherapy. / Brothwell, M. R.S.; West, C. M.; Dunning, A. M.; Burnet, N. G.; Barnett, G. C.

In: Clinical Oncology, Vol. 31, No. 5, 01.05.2019, p. 319-325.

Research output: Contribution to journalArticlepeer-review

Harvard

Brothwell, MRS, West, CM, Dunning, AM, Burnet, NG & Barnett, GC 2019, 'Radiogenomics in the Era of Advanced Radiotherapy', Clinical Oncology, vol. 31, no. 5, pp. 319-325. https://doi.org/10.1016/j.clon.2019.02.006

APA

Brothwell, M. R. S., West, C. M., Dunning, A. M., Burnet, N. G., & Barnett, G. C. (2019). Radiogenomics in the Era of Advanced Radiotherapy. Clinical Oncology, 31(5), 319-325. https://doi.org/10.1016/j.clon.2019.02.006

Vancouver

Brothwell MRS, West CM, Dunning AM, Burnet NG, Barnett GC. Radiogenomics in the Era of Advanced Radiotherapy. Clinical Oncology. 2019 May 1;31(5):319-325. https://doi.org/10.1016/j.clon.2019.02.006

Author

Brothwell, M. R.S. ; West, C. M. ; Dunning, A. M. ; Burnet, N. G. ; Barnett, G. C. / Radiogenomics in the Era of Advanced Radiotherapy. In: Clinical Oncology. 2019 ; Vol. 31, No. 5. pp. 319-325.

Bibtex

@article{18afd5804e5e4f72a6610fd630c4803a,
title = "Radiogenomics in the Era of Advanced Radiotherapy",
abstract = "Most radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.",
keywords = "Genome-wide association studies, radiogenomics, radiotherapy toxicity",
author = "Brothwell, {M. R.S.} and West, {C. M.} and Dunning, {A. M.} and Burnet, {N. G.} and Barnett, {G. C.}",
year = "2019",
month = may,
day = "1",
doi = "10.1016/j.clon.2019.02.006",
language = "English",
volume = "31",
pages = "319--325",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Co. Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Radiogenomics in the Era of Advanced Radiotherapy

AU - Brothwell, M. R.S.

AU - West, C. M.

AU - Dunning, A. M.

AU - Burnet, N. G.

AU - Barnett, G. C.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Most radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.

AB - Most radiogenomics studies investigate how genetic variation can help to explain the differences in early and late radiotherapy toxicity between individuals. The field of radiogenomics in photon beam therapy has grown rapidly in recent years, carving out a unique translational discipline, which has progressed from candidate gene studies to larger scale genome-wide association studies, meta-analyses and now prospective validation studies. Genotyping is increasingly sophisticated and affordable, and whole-genome sequencing may soon become readily available as a diagnostic tool in the clinic. The ultimate aim of radiogenomics research is to tailor treatment to the individual with a test based on a combination of treatment, clinical and genetic factors. This personalisation would allow the greatest tumour control while minimising acute and long-term toxicity. Here we discuss the evolution of the field of radiogenomics with reference to the most recent developments and challenges.

KW - Genome-wide association studies

KW - radiogenomics

KW - radiotherapy toxicity

U2 - 10.1016/j.clon.2019.02.006

DO - 10.1016/j.clon.2019.02.006

M3 - Article

C2 - 30914148

AN - SCOPUS:85062883542

VL - 31

SP - 319

EP - 325

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 5

ER -